154 related articles for article (PubMed ID: 35947165)
1. Immune phenotypes and checkpoint molecule expression of clonally expanded lymph node-infiltrating T cells in classical Hodgkin lymphoma.
Ballhausen A; Ben Hamza A; Welters C; Dietze K; Bullinger L; Rahn HP; Hartmann S; Hansmann ML; Hansmann L
Cancer Immunol Immunother; 2023 Feb; 72(2):515-521. PubMed ID: 35947165
[TBL] [Abstract][Full Text] [Related]
2. Localization-associated immune phenotypes of clonally expanded tumor-infiltrating T cells and distribution of their target antigens in rectal cancer.
Penter L; Dietze K; Ritter J; Lammoglia Cobo MF; Garmshausen J; Aigner F; Bullinger L; Hackstein H; Wienzek-Lischka S; Blankenstein T; Hummel M; Dornmair K; Hansmann L
Oncoimmunology; 2019; 8(6):e1586409. PubMed ID: 31069154
[TBL] [Abstract][Full Text] [Related]
3. Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma.
Welters C; Lammoglia Cobo MF; Stein CA; Hsu MT; Ben Hamza A; Penter L; Chen X; Buccitelli C; Popp O; Mertins P; Dietze K; Bullinger L; Moosmann A; Blanc E; Beule D; Gerbitz A; Strobel J; Hackstein H; Rahn HP; Dornmair K; Blankenstein T; Hansmann L
Cancer Immunol Res; 2022 Nov; 10(11):1407-1419. PubMed ID: 36122410
[TBL] [Abstract][Full Text] [Related]
4. A Systematic Review of the Tumor-Infiltrating CD8
Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
Front Immunol; 2021; 12():734956. PubMed ID: 34603316
[TBL] [Abstract][Full Text] [Related]
5. The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy.
Alonso-Álvarez S; Vidriales MB; Caballero MD; Blanco O; Puig N; Martin A; Peñarrubia MJ; Zato E; Galende J; Bárez A; Alcoceba M; Orfão A; González M; García-Sanz R
Leuk Lymphoma; 2017 May; 58(5):1144-1152. PubMed ID: 27733075
[TBL] [Abstract][Full Text] [Related]
6. Complex Immune Evasion Strategies in Classical Hodgkin Lymphoma.
Wein F; Weniger MA; Höing B; Arnolds J; Hüttmann A; Hansmann ML; Hartmann S; Küppers R
Cancer Immunol Res; 2017 Dec; 5(12):1122-1132. PubMed ID: 29070649
[TBL] [Abstract][Full Text] [Related]
7. CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2: Characterizing CD4+ T cells in Hodgkin lymphoma.
Veldman J; Rodrigues Plaça J; Chong L; Terpstra MM; Mastik M; van Kempen LC; Kok K; Aoki T; Steidl C; van den Berg A; Visser L; Diepstra A
Oncoimmunology; 2022; 11(1):2033433. PubMed ID: 35111387
[TBL] [Abstract][Full Text] [Related]
8. Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.
El Halabi L; Adam J; Gravelle P; Marty V; Danu A; Lazarovici J; Ribrag V; Bosq J; Camara-Clayette V; Laurent C; Ghez D
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):257-266.e3. PubMed ID: 33277223
[TBL] [Abstract][Full Text] [Related]
9. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.
Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM
Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of PD-1 blockade in cervical cancer is related to a CD8
Heeren AM; Rotman J; Stam AGM; Pocorni N; Gassama AA; Samuels S; Bleeker MCG; Mom CH; Zijlmans HJMAA; Kenter GG; Jordanova ES; de Gruijl TD
J Immunother Cancer; 2019 Feb; 7(1):43. PubMed ID: 30755279
[TBL] [Abstract][Full Text] [Related]
11. Expression of Sirt1 and FoxP3 in classical Hodgkin lymphoma and tumor infiltrating lymphocytes: Implications for immune dysregulation, prognosis and potential therapeutic targeting.
Quesada AE; Assylbekova B; Jabcuga CE; Zhang R; Covinsky M; Rios A; Nguyen ND; Brown RE
Int J Clin Exp Pathol; 2015; 8(10):13241-8. PubMed ID: 26722524
[TBL] [Abstract][Full Text] [Related]
12. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028
[TBL] [Abstract][Full Text] [Related]
13. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
15. Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy.
Fransen MF; Schoonderwoerd M; Knopf P; Camps MG; Hawinkels LJ; Kneilling M; van Hall T; Ossendorp F
JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518694
[TBL] [Abstract][Full Text] [Related]
16. Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8
Greenbaum AM; Fromm JR; Gopal AK; Houghton AM
Blood Res; 2022 Jun; 57(2):117-128. PubMed ID: 35551108
[TBL] [Abstract][Full Text] [Related]
17. Mass cytometry of Hodgkin lymphoma reveals a CD4
Cader FZ; Schackmann RCJ; Hu X; Wienand K; Redd R; Chapuy B; Ouyang J; Paul N; Gjini E; Lipschitz M; Armand P; Wu D; Fromm JR; Neuberg D; Liu XS; Rodig SJ; Shipp MA
Blood; 2018 Aug; 132(8):825-836. PubMed ID: 29880615
[TBL] [Abstract][Full Text] [Related]
18. Integrated TCR repertoire analysis and single-cell transcriptomic profiling of tumor-infiltrating T cells in renal cell carcinoma identifies shared and tumor-restricted expanded clones with unique phenotypes.
Xu Y; Morales AJ; Towlerton AMH; Akilesh S; Miller CP; Tykodi SS; Warren EH
Front Oncol; 2022; 12():952252. PubMed ID: 36185254
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
[TBL] [Abstract][Full Text] [Related]
20. Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma.
Aoki T; Chong LC; Takata K; Milne K; Marshall A; Chavez EA; Miyata-Takata T; Ben-Neriah S; Unrau D; Telenius A; Boyle M; Weng AP; Savage KJ; Scott DW; Farinha P; Shah SP; Nelson BH; Steidl C
Proc Natl Acad Sci U S A; 2021 Oct; 118(41):. PubMed ID: 34615710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
